Novo Nordisk Boosts Wegovy Access with Telehealth Partnerships

Published 1 days agoNVO

Novo Nordisk Boosts Wegovy Access with Telehealth Partnerships

Novo Nordisk is expanding the reach of its popular weight-loss drug, Wegovy, by partnering with telehealth companies Hims & Hers, Ro, and LifeMD. This strategic move aims to make Wegovy more accessible to cash-paying customers by utilizing telehealth platforms, allowing for convenient access to the branded medication, Reuters reported.

The initiative comes in response to recent regulatory changes that limit the production of compounded obesity treatments. A U.S. judge's ruling has potentially increased restrictions on these alternatives, prompting Novo Nordisk to ensure that Wegovy remains available to those seeking effective, FDA-approved weight-loss solutions. Through the NovoCare Pharmacy program, Wegovy is now available at a reduced cost of $499 per month, providing an affordable option for patients without insurance or coverage for obesity medications.

This expansion strategy has had an immediate impact on the market, as evidenced by a nearly 30% jump in premarket trading for Hims & Hers stock. The collaboration is expected to enhance patient's access to Wegovy while adapting to changing market and regulatory conditions, strengthening Novo Nordisk's foothold in the weight-loss drug market.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Eli Lilly Sees Robust Sales from Diabetes Drug, Adjusts Profit Forecast

Eli Lilly Sees Robust Sales from Diabetes Drug, Adjusts Profit Forecast

15 minutes agoLLY

Eli Lilly has reported a solid performance in the last quarter of 2024, particularly fueled by its diabetes drug, Mounjaro, which achieved a remarkable 60% increase in sales, totaling $3.53 billion. However, Reuters noted that sales of its weight-loss drug, Zepbound, fell short of expectations, coming in at $2.31 billion compared to the anticipated $2.33 billion figure. The company has responded to these mixed results by adjusting its annual profit outlook. Due to Zepbound's underperformance and heightened competition, Eli Lilly revised its adjusted profit forecast from $22.50–$24.00 per share down to a range of $20.78–$22.28 per share, as reported by Reuters. Alongside these adjustments, Eli Lilly is actively looking to diversify its offerings by potentially acquiring Scorpion Therapeutics for up to $2.5 billion to strengthen its cancer treatment portfolio. Despite facing challenges, Eli Lilly maintains its status as the most valuable healthcare company globally, with a market cap exceeding $800 billion. As part of its strategic expansion, Eli Lilly aims to leverage its strong position to innovate beyond its current major revenue drivers. This strategy is evident through its ongoing discussions to acquire Scorpion Therapeutics, indicating a commitment to broadening its scope beyond diabetes and obesity drugs.

Applied Industrial Technologies Reports Q3 EPS Growth Amid Sales Dip

Applied Industrial Technologies Reports Q3 EPS Growth Amid Sales Dip

29 minutes agoAIT

Applied Industrial Technologies has released its fiscal Q3 2025 earnings, showcasing a notable increase in earnings per share (EPS). The company reported an EPS of $2.39, marking a 6.7% increase from the same period last year, according to tipranks.com. Despite a challenging sales environment, the company displayed strong financial discipline, highlighted by a gross margin of approximately 31% and an EBITDA margin above 13%. However, there was a 2% dip in organic daily sales compared to the previous year. Although sales faced a slight decline, Applied Industrial Technologies maintained its profitability through margin expansion. As Investing.com reported, the Service Center segment contributed positively with resilient growth, while the Engineered Solutions segment faced challenges, particularly in fluid power operations. In addition to earnings news, the company announced an increase in its quarterly cash dividend by 24%, now set at $0.46 per share, rewarding shareholders even amid sales challenges. Looking ahead, the company has projected its fiscal 2025 EPS to be in the range of $9.20 to $9.95, with total sales expected to fluctuate between a decline of 2.5% to an increase of 2.5%. This guidance includes expectations for sales to decline in the early part of the fiscal year, stabilize in the third quarter, and resume growth in the fourth quarter. These strategic adjustments indicate the company's efforts to balance operational performance and shareholder value.

GM Lowers 2025 Profit Forecast Due to Tariff Concerns

GM Lowers 2025 Profit Forecast Due to Tariff Concerns

44 minutes agoGM

General Motors has cut its 2025 profit forecast, citing the hefty financial burden of newly adjusted automotive tariffs. The company now predicts an annual adjusted core profit in the range of $10 billion to $12.5 billion, a significant drop from initial forecasts of $13.7 billion to $15.7 billion. With expected tariff-related costs ranging from $4 billion to $5 billion, the revised numbers reflect a tough market environment. Reuters reported these newly imposed tariffs are complicating financial projections for several major automakers. Alongside the decline in profit forecast, GM has also adjusted its net income estimates. The automaker expects to see an annual net income between $8.2 billion and $10.1 billion, reduced from earlier projections of $11.2 billion to $12.5 billion. The ripple effects of U.S. President Donald Trump's evolving trade policies and a steep 25% tariff on imported vehicles have even led companies like Stellantis and Mercedes-Benz to withdraw their profit forecasts altogether. CEO Mary Barra addressed these challenges, emphasizing GM's ongoing dialogue with the Trump administration and international trade partners to manage these policy shifts. Despite these efforts, GM's stock took a hit amidst investor worries over the updated financial outlook.

Moderna Posts Q1 2025 Loss on Plummeting Vaccine Sales

Moderna Posts Q1 2025 Loss on Plummeting Vaccine Sales

59 minutes agoMRNA

Moderna reported a first-quarter 2025 net loss of $1.18 billion, translating to a loss of $3.07 per share. This decline was accompanied by revenue figures of $167 million, a sharp fall from the $1.86 billion recorded in the same quarter the previous year. NBC New York noted these results reflected weaker demand for its COVID-19 vaccine during the period. The steep decline in COVID-19 vaccine sales—down about 90% from the previous year—primarily drove the revenue decrease. Additionally, the sales for Moderna's respiratory syncytial virus vaccine, mRESVIA, did not meet expectations, according to Reuters. These challenges highlight the hurdles Moderna faces as it adjusts to diminishing demand in its core product areas. In response to these challenges, Moderna has enacted cost-cutting strategies aimed at reducing adjusted operating costs by $1.7 billion by 2027, with a plan to trim down cash costs by $1 billion in 2025. Despite the current struggles, the company maintains its full-year revenue projection of $1.5 to $2.5 billion, anticipating increased demand later in the year. Additionally, Moderna is preparing for a potential U.S. regulatory approval of a combination COVID-19 and flu vaccine by 2026, indicating efforts towards product diversification.